| Field | Specification |
|---|---|
| Target | |
| Alternative names | Insulin receptor substrate 1; IRS-1; IRS1 |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human IRS1 recombinant protein (Position: S1041-Q1242). Human IRS1 shares 78% and 80% amino acid (aa) sequence identity with mouse and rat IRS1, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone 10I3 is a mouse monoclonal antibody that recognizes insulin receptor substrate 1 (gene IRS1) in human samples and is validated for Western blot, IHC, ICC/IF and flow cytometry. The predicted molecular weight is 131.6 kDa, and the supplier reports an observed band at about 160–180 kDa.
Insulin receptor substrate 1 (IRS1) is an adaptor protein phosphorylated on tyrosine by the insulin and IGF-1 receptors. Phosphorylated IRS1 recruits PI3K and GRB2, relaying signals to the AKT and MAPK pathways that control glucose uptake, metabolism and growth. Inhibitory serine phosphorylation of IRS1 is a common readout in insulin resistance research.
| Target | Insulin receptor substrate 1 (gene IRS1; UniProt P35568, human) |
|---|---|
| Clone | 10I3 |
| Host / Clonality / Isotype | Mouse / Monoclonal / Mouse IgG2a |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3 |
| Calculated MW | 131.6 kDa |
| Observed MW | 160–180 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells |
Samples with a confirmed band (WB): human A549 cells, human T-47D cells, human Caco-2 cells, human SW620 cells, human HeLa cells, human Raji cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human colon cancer tissue, human lung cancer tissue, human placenta tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with confirmed staining (ICC/IF): MCF-7 cells.
Samples with a confirmed signal (flow cytometry): PC-3 cells, U2OS cells.
Immunogen
Recombinant human IRS1 fragment (Ser1041–Gln1242), expressed in E. coli. Sequence identity with the mouse and rat orthologs: 78% and 80%, respectively.
Reactivity Notes
The supplier lists reactivity with human. UniProt places insulin receptor substrate 1 in the cytoplasm and nucleus. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
